Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

Massimo Iavarone, Federica Invernizzi, Carolin Czauderna, Marco Sanduzzi-Zamparelli, Sherrie Bhoori, Giuliana Amaddeo, Matteo A. Manini, Miguel F. López, Margarita Anders, Matthias Pinter, Maria J.B. Rodríguez, Mario R. Cristóbal, Gabriel A. Soteras, Federico Piñero, Gerda E. Villadsen, Arndt Weinmann, Gonzalo Crespo, Vincenzo Mazzaferro, Helene Regnault, Massimo De GiorgioMaria L. González-Diéguez, Maria F. Donato, Maria Varela, Marcus Alexander Wörns, Jordi Bruix, Pietro Lampertico, Maria Reig

Research output: Contribution to journalArticle

Abstract

Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib-treated LT patients (2015-2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7% cirrhotics, 54% performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; median time on sorafenib was 11.3 (0.7-76.4) months and 14 (1-591) days from sorafenib discontinuation to regorafenib. During regorafenib (6.3 months), all patients had at least one adverse event (AE), the most common grade 3/4 AEs were fatigue (n = 7) and dermatological reaction (n = 5). While no liver rejection was observed, plasma levels of immunosuppressive drugs increased in five. Twenty-four patients developed progression (38% extrahepatic growth, 33% new extrahepatic lesions/vascular invasion). Median OS from regorafenib initiation was 12.9 (95% CI, 6.7-19.1) and 38.4 months (95% CI, 18.5-58.4) for the sorafenib initiation. This is the first study showing safety of regorafenib after LT, thus providing the rational of considering regorafenib in the clinical decision-making in sorafenib-tolerant patients with HCC recurrence after LT.

Original languageEnglish
Pages (from-to)3176-3184
JournalAmerican Journal of Transplantation
Volume19
Issue number11
DOIs
Publication statusPublished - 2019

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Safety
regorafenib
sorafenib
Recurrence
Survival
Immunosuppressive Agents
Multicenter Studies
Fatigue
Blood Vessels
Therapeutics
Liver
Growth
Pharmaceutical Preparations

Keywords

  • cancer/malignancy/neoplasia
  • chemotherapy
  • clinical research/practice
  • drug interaction
  • liver transplantation/hepatology
  • pharmacology
  • side effects

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. / Iavarone, Massimo; Invernizzi, Federica; Czauderna, Carolin; Sanduzzi-Zamparelli, Marco; Bhoori, Sherrie; Amaddeo, Giuliana; Manini, Matteo A.; López, Miguel F.; Anders, Margarita; Pinter, Matthias; Rodríguez, Maria J.B.; Cristóbal, Mario R.; Soteras, Gabriel A.; Piñero, Federico; Villadsen, Gerda E.; Weinmann, Arndt; Crespo, Gonzalo; Mazzaferro, Vincenzo; Regnault, Helene; Giorgio, Massimo De; González-Diéguez, Maria L.; Donato, Maria F.; Varela, Maria; Wörns, Marcus Alexander; Bruix, Jordi; Lampertico, Pietro; Reig, Maria.

In: American Journal of Transplantation, Vol. 19, No. 11, 2019, p. 3176-3184.

Research output: Contribution to journalArticle

Iavarone, M, Invernizzi, F, Czauderna, C, Sanduzzi-Zamparelli, M, Bhoori, S, Amaddeo, G, Manini, MA, López, MF, Anders, M, Pinter, M, Rodríguez, MJB, Cristóbal, MR, Soteras, GA, Piñero, F, Villadsen, GE, Weinmann, A, Crespo, G, Mazzaferro, V, Regnault, H, Giorgio, MD, González-Diéguez, ML, Donato, MF, Varela, M, Wörns, MA, Bruix, J, Lampertico, P & Reig, M 2019, 'Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation', American Journal of Transplantation, vol. 19, no. 11, pp. 3176-3184. https://doi.org/10.1111/ajt.15551
Iavarone, Massimo ; Invernizzi, Federica ; Czauderna, Carolin ; Sanduzzi-Zamparelli, Marco ; Bhoori, Sherrie ; Amaddeo, Giuliana ; Manini, Matteo A. ; López, Miguel F. ; Anders, Margarita ; Pinter, Matthias ; Rodríguez, Maria J.B. ; Cristóbal, Mario R. ; Soteras, Gabriel A. ; Piñero, Federico ; Villadsen, Gerda E. ; Weinmann, Arndt ; Crespo, Gonzalo ; Mazzaferro, Vincenzo ; Regnault, Helene ; Giorgio, Massimo De ; González-Diéguez, Maria L. ; Donato, Maria F. ; Varela, Maria ; Wörns, Marcus Alexander ; Bruix, Jordi ; Lampertico, Pietro ; Reig, Maria. / Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. In: American Journal of Transplantation. 2019 ; Vol. 19, No. 11. pp. 3176-3184.
@article{309b9937bf004c9fb50b7974d0a5b33c,
title = "Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation",
abstract = "Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib-treated LT patients (2015-2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7{\%} cirrhotics, 54{\%} performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; median time on sorafenib was 11.3 (0.7-76.4) months and 14 (1-591) days from sorafenib discontinuation to regorafenib. During regorafenib (6.3 months), all patients had at least one adverse event (AE), the most common grade 3/4 AEs were fatigue (n = 7) and dermatological reaction (n = 5). While no liver rejection was observed, plasma levels of immunosuppressive drugs increased in five. Twenty-four patients developed progression (38{\%} extrahepatic growth, 33{\%} new extrahepatic lesions/vascular invasion). Median OS from regorafenib initiation was 12.9 (95{\%} CI, 6.7-19.1) and 38.4 months (95{\%} CI, 18.5-58.4) for the sorafenib initiation. This is the first study showing safety of regorafenib after LT, thus providing the rational of considering regorafenib in the clinical decision-making in sorafenib-tolerant patients with HCC recurrence after LT.",
keywords = "cancer/malignancy/neoplasia, chemotherapy, clinical research/practice, drug interaction, liver transplantation/hepatology, pharmacology, side effects",
author = "Massimo Iavarone and Federica Invernizzi and Carolin Czauderna and Marco Sanduzzi-Zamparelli and Sherrie Bhoori and Giuliana Amaddeo and Manini, {Matteo A.} and L{\'o}pez, {Miguel F.} and Margarita Anders and Matthias Pinter and Rodr{\'i}guez, {Maria J.B.} and Crist{\'o}bal, {Mario R.} and Soteras, {Gabriel A.} and Federico Pi{\~n}ero and Villadsen, {Gerda E.} and Arndt Weinmann and Gonzalo Crespo and Vincenzo Mazzaferro and Helene Regnault and Giorgio, {Massimo De} and Gonz{\'a}lez-Di{\'e}guez, {Maria L.} and Donato, {Maria F.} and Maria Varela and W{\"o}rns, {Marcus Alexander} and Jordi Bruix and Pietro Lampertico and Maria Reig",
year = "2019",
doi = "10.1111/ajt.15551",
language = "English",
volume = "19",
pages = "3176--3184",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

AU - Iavarone, Massimo

AU - Invernizzi, Federica

AU - Czauderna, Carolin

AU - Sanduzzi-Zamparelli, Marco

AU - Bhoori, Sherrie

AU - Amaddeo, Giuliana

AU - Manini, Matteo A.

AU - López, Miguel F.

AU - Anders, Margarita

AU - Pinter, Matthias

AU - Rodríguez, Maria J.B.

AU - Cristóbal, Mario R.

AU - Soteras, Gabriel A.

AU - Piñero, Federico

AU - Villadsen, Gerda E.

AU - Weinmann, Arndt

AU - Crespo, Gonzalo

AU - Mazzaferro, Vincenzo

AU - Regnault, Helene

AU - Giorgio, Massimo De

AU - González-Diéguez, Maria L.

AU - Donato, Maria F.

AU - Varela, Maria

AU - Wörns, Marcus Alexander

AU - Bruix, Jordi

AU - Lampertico, Pietro

AU - Reig, Maria

PY - 2019

Y1 - 2019

N2 - Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib-treated LT patients (2015-2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7% cirrhotics, 54% performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; median time on sorafenib was 11.3 (0.7-76.4) months and 14 (1-591) days from sorafenib discontinuation to regorafenib. During regorafenib (6.3 months), all patients had at least one adverse event (AE), the most common grade 3/4 AEs were fatigue (n = 7) and dermatological reaction (n = 5). While no liver rejection was observed, plasma levels of immunosuppressive drugs increased in five. Twenty-four patients developed progression (38% extrahepatic growth, 33% new extrahepatic lesions/vascular invasion). Median OS from regorafenib initiation was 12.9 (95% CI, 6.7-19.1) and 38.4 months (95% CI, 18.5-58.4) for the sorafenib initiation. This is the first study showing safety of regorafenib after LT, thus providing the rational of considering regorafenib in the clinical decision-making in sorafenib-tolerant patients with HCC recurrence after LT.

AB - Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib-treated LT patients (2015-2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7% cirrhotics, 54% performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; median time on sorafenib was 11.3 (0.7-76.4) months and 14 (1-591) days from sorafenib discontinuation to regorafenib. During regorafenib (6.3 months), all patients had at least one adverse event (AE), the most common grade 3/4 AEs were fatigue (n = 7) and dermatological reaction (n = 5). While no liver rejection was observed, plasma levels of immunosuppressive drugs increased in five. Twenty-four patients developed progression (38% extrahepatic growth, 33% new extrahepatic lesions/vascular invasion). Median OS from regorafenib initiation was 12.9 (95% CI, 6.7-19.1) and 38.4 months (95% CI, 18.5-58.4) for the sorafenib initiation. This is the first study showing safety of regorafenib after LT, thus providing the rational of considering regorafenib in the clinical decision-making in sorafenib-tolerant patients with HCC recurrence after LT.

KW - cancer/malignancy/neoplasia

KW - chemotherapy

KW - clinical research/practice

KW - drug interaction

KW - liver transplantation/hepatology

KW - pharmacology

KW - side effects

UR - http://www.scopus.com/inward/record.url?scp=85071745261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071745261&partnerID=8YFLogxK

U2 - 10.1111/ajt.15551

DO - 10.1111/ajt.15551

M3 - Article

C2 - 31365177

AN - SCOPUS:85071745261

VL - 19

SP - 3176

EP - 3184

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 11

ER -